iiCON is a world leading centre for infection innovation and R&D – working with industry, academics, and clinicians to save and improve lives around the world by supporting innovation and progressing the development of antimicrobial products and treatments.

Operating across eleven commercially sustainable specialist research platforms, iiCON’s collaborative effort is directly reducing the global burden of infectious disease with a coordinated initiative to address key roadblocks in global R&D pipelines and strengthen and regenerate the global anti-infectives supply chain.

iiCON provides access to eleven commercially sustainable specialist research platforms, co-developed and operated by our industrial, academic, and clinical partners.

Founding Director of iiCON and Professor of Tropical Medicine at LSTM, Professor Hemingway was appointed the Director of LSTM in 2001 and stepped down in 2019 having overseen a period of exceptional growth of the organisation.

iiCON ANNUAL REPORT 2024 6 Overview iiCON pays close attention to the infection research and development (R&D) network trends globally. Monitoring the key players, tracking who is moving into the space, and where organisations are based provides vital insight into upcoming opportunities. At a glance iiCON has access to a diverse and expansive ...

iiCON Annual Report 2024 Click below to read and download our latest annual report, exploring achievements and activity from October 2023 to October 2024. Click here to download report

After successful sandpit events in Liverpool and London earlier this year, iiCON (Infection Innovation Consortium) is excited to announce 11 new projects. These projects are focused on combating infectious diseases and have received a share of £1.5 million in funding from the UKRI as part of its ongoing work to support innovative ways of ...

iiCON’s Surfaces Platform supported the Ministry of Defence to validate a cheap, effective disinfectant, Virusend, that inactivates coronavirus in 60 seconds. The environmentally friendly antiviral spray underwent five weeks of rigorous testing within Category 3 …

Infection Innovation Consortium (iiCON), Liverpool Life Sciences Accelerator, 1 Daulby Street, Liverpool L7 8XZ. [email protected]

iiCON is excited to announce the launch of a procurement tender to seek expressions of interest to develop the Category Three robotic laboratories, which will be capable of handling a variety of dangerous and deadly pathogens.